Report
Pharma Mar : Q2 earnings in line
>Headline momentum appears weak but Lurbi keeps growing in underlying terms - Sales decreased 7% y-o-y in Q2 2024 (vs +12% in Q1 and -20% in Q4). Biopharma sales decreased 18% y-o-y in Q2 2024 (compared to +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect H1 2024 Lurbi sales in Europe is growing at a +16% pace. Royalties posted a +18% y-o-y increase (vs ...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.